BioNTech SE Sponsored ADR (BNTX) shares ended the last trading session 11% higher at $208.90. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 57.8% gain over the past four weeks.
The stock rallied driven by optimism over the news that the European Medicines Agency will condict an accelerated assessment of the company's two-shot COVID-19 vaccine, which is being jointly developed with Pfizer, for use in children aged between 12 to 15 years.
Price and Consensus
This company is expected to post quarterly earnings of $3.44 per share in its upcoming report, which represents a year-over-year change of +1423.1%. Revenues are expected to be $1.92 billion, up 6191% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For BioNTech SE Sponsored ADR, the consensus EPS estimate for the quarter has been revised 123.1% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BNTX going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank 3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
